[A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin].

Abstract

Were port a 51-year-old male left renal pelvic cancer patient with paclitaxel (PTX)-induced peripheral neuropathy, which was successfully treated with pregabalin. From June 2010, a gemcitabine/PTX (GP) regimen was used as third-line treatment. In order to relieve the PTX-induced peripheral neuropathy, pregabalin (75mg/day, at night) was administered from day 6 of the 16th course. Moreover, pregabalin was increased to 150mg/day from day 12 of the course. Sensory neurotoxicity after the administration of pregabalin was decreased from CTCAE (version 4. 0) grade 3 to 1 at day 19 of the course. Therefore, there is a possibility that the PTX -induced peripheral neuropathy may be improved by pregabalin administration. Further trials may be needed to confirm the value of pregabalin.

• Authors: Toshihisa Nakashima, Takayoshi Kiba, Yoshikazu Ogawa, Atsuko Hosokawa, Hiromi Shintani, Yuuko Okada, Takako Taniguchi, Masanobu Shigeta, Kazuhiro Kozawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 9 Pg. 1443-5 (Sep 2012) ISSN: 0385-0684 [Print] Japan
• PMID: 22996788 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Pregabalin
• gamma-Aminobutyric Acid
• Paclitaxel

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Kidney Neoplasms (drug therapy, pathology, surgery)
• Male
• Middle Aged
• Neoplasm Staging
• Paclitaxel (administration & dosage, adverse effects)
• Peripheral Nervous System Diseases (chemically induced, drug therapy)
• Pregabalin
• gamma-Aminobutyric Acid (analogs & derivatives, therapeutic use)